Tumor-Associated Glycans and Immune Surveillance

Vaccines

Behjatolah Monzavi-Karbassi²  Anastas Pashov¹ 

[1] Stephan Angeloff Institute of Microbiology, BAS, Sofia 1113, Bulgaria;Winthrop P. Rockefeller Cancer Institute and Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

关键词: monoclonal antibodies;    immunotherapy;    cancer;    mimics;    vaccine;    TACA;    glycans;    tumor;    carbohydrate;   

DOI  :  10.3390/vaccines1020174

来源: mdpi

【 摘 要 】

Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.